Thrombin-Based Hemostatic Agent in Primary Total Knee Arthroplasty

Abstract

The present meta-analysis pooled the results from randomized controlled trials (RCTs) to identify and assess the efficacy and safety of thrombin-based hemostatic agent in primary total knee arthroplasty (TKA). Potential academic articles were identified from the Cochrane Library, Medline (1966-2015.5), PubMed (1966-2015.5), Embase (1980-2015.5), and ScienceDirect (1966-2015.5). Relevant journals and the recommendations of expert panels were also searched by using Google search engine. RCTs assessing the efficacy and safety of thrombin-based hemostatic agent in primary TKA were included. Pooling of data was analyzed by RevMan 5.1 (The Cochrane Collaboration, Oxford, UK). A total of four RCTs met the inclusion criteria. The meta-analysis revealed significant differences in postoperative hemoglobin decline (p < 0.00001), total blood loss (p < 0.00001), drainage volume (p = 0.01), and allogenic blood transfusion (p = 0.01) between the treatment group and the control group. No significant differences were found regarding incidence of infection (p = 0.45) and deep vein thrombosis (DVT; p = 0.80) between the groups. Meta-analysis indicated that the application of thrombin-based hemostatic agent before wound closure decreased postoperative hemoglobin decline, drainage volume, total blood loss, and transfusion rate and did not increase the risk of infection, DVT, or other complications. Therefore, the reviewers believe that thrombin-based hemostatic agent is effective and safe in primary TKA.

Keywords

thrombin - hemostasis - total knee arthroplasty - blood loss - meta-analysis

Note

Xin Fu and Peng Tian contributed equally to this work.

• Reference

• 1 Wang C, Han Z, Zhang T , et al. The efficacy of a thrombin-based hemostatic agent in primary total knee arthroplasty: a meta-analysis. J Orthop Surg 2014; 9: 90
• 2 Kodadek M. Managing osteoarthritis. Nurs Womens Health 2015; 19 (1) 71-76
• 3 Shan L, Shan B, Suzuki A, Nouh F, Saxena A. Intermediate and long-term quality of life after total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Am 2015; 97 (2) 156-168
• 4 Bong MR, Patel V, Chang E, Issack PS, Hebert R, Di Cesare PE. Risks associated with blood transfusion after total knee arthroplasty. J Arthroplasty 2004; 19 (3) 281-287
• 5 Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113 (15) 3406-3417
• 6 Liu J, Cao JG, Wang L, Ma XL. Effect of fibrin sealant on blood loss following total knee arthroplasty: a systematic review and meta-analysis. Int J Surg 2014; 12 (2) 95-102
• 7 Echave M, Oyagüez I, Casado MA. Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review. BMC Surg 2014; 14: 111
• 8 Gazzeri R, Galarza M, Alfier A. Safety biocompatibility of gelatin hemostatic matrix (Floseal and Surgiflo) in neurosurgical procedures. Surg Technol Int 2012; 22: 49-54
• 9 Sartelli M, Catena F, Biancafarina A , et al. Use of Floseal hemostatic matrix for control of hemostasis during laparoscopic cholecystectomy for acute cholecystitis: a multicenter historical control group comparison (the GLA study gelatin matrix for acute cholecystitis). J Laparoendosc Adv Surg Tech A 2014; 24 (12) 837-841
• 10 Testini M, Marzaioli R, Lissidini G , et al. The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg 2009; 394 (5) 837-842
• 11 Bae KC, Cho CH, Lee KJ , et al. Efficacy of intra-articular injection of thrombin-based hemostatic agent in the control of bleeding after primary total knee arthroplasty. Knee Surg Relat Res 2014; 26 (4) 236-240
• 12 Comadoll JL, Comadoll S, Hutchcraft A , et al. Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKA. Orthopedics 2012; 35 (6) e785-e793
• 13 Di Francesco A, Flamini S, Fiori F, Mastri F. Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial. Indian J Orthop 2013; 47 (5) 474-481
• 14 Helito CP, Gobbi RG, Castrillon LM, Hinkel BB, Pécora JR, Camanho GL. Comparison of Floseal(r) and electrocautery in hemostasis after total knee arthroplasty. Acta Ortop Bras 2013; 21 (6) 320-322
• 15 Kim HJ, Fraser MR, Kahn B, Lyman S, Figgie MP. The efficacy of a thrombin-based hemostatic agent in unilateral total knee arthroplasty: a randomized controlled trial. J Bone Joint Surg Am 2012; 94 (13) 1160-1165
• 16 Suarez JC, Slotkin EM, Alvarez AM, Szubski CR, Barsoum WK, Patel PD. Prospective, randomized trial to evaluate efficacy of a thrombin-based hemostatic agent in total knee arthroplasty. J Arthroplasty 2014; 29 (10) 1950-1955
• 17 Schwab PE, Thienpont E. Use of a haemostatic matrix (Floseal(®)) does not reduce blood loss in minimally invasive total knee arthroplasty performed under continued aspirin. Blood Transfus 2015; 1-7